Volume : 11, Issue : 02, February – 2024
Title:
A REVIEW ARTICLE ON BREXANOLONE DRUG-ANTI DEPRESSANT
Authors :
G. Meghana, R. Jona Methusula
Abstract :
ZULRESSO (Brexanolone) is a novel FDA-approved treatment for moderate-to-severe postpartum depression. Postpartum depression may be diagnosed in women experiencing depressive symptoms which can manifest as cognitive, behavioural, or emotional disturbances as early as the third trimester to 4 weeks following delivery. The efficacy of brexanolone suggests that neurosteroids such as allopregnanolone are important to treat PPD. However, it is currently unclear if brexanolone provides lasting relief of depressive symptoms at or beyond 30 days following administration. Further studies are necessary to make this determination.
Cite This Article:
Please cite this article in press G. Meghana et al. , A Review Article On Brexanolone Drug-Anti Depressant, Indo Am. J. P. Sci, 2024; 11 (02).
Number of Downloads : 10
References:
1.Preclinical and clinical pharmacology of brexanolone (allopregnanolone) for postpartum depression: a landmark journey from concept to clinic in neurosteroid … DS Reddy, RH Mbilinyi, E EPsychopharmacology, 2023•Springer
2. Y Azhar, AU Din – 2019 – europepmc.org Objectives: Outline the indications for brexanolone. Describe the dosing of brexanolone. Identify the most common adverse effects of brexanolone therapy. Review the importance of Brexanolone: a novel therapeutic in the treatment of postpartum depression… Dacarett-Galeano is a fourth-year medical student at the Icahn School of Medicine at Mount Sinai, New York. Dr. Diao is a third-year resident in the Department of Psychiatry at the Icahn …
4. Establishment of a High Throughput Screening System for GABAA1 Modulators in Living Cells
Y Zhang, T Shi, X Chen, R Zhang, J Shi, Q Jin, J Xu, C Wang, L Li, Combinatorial Chemistry & High Throughput Screening, 2023•ingentaconnect.com
5. Brexanolone therapeutics in post-partum depression involves inhibition of systemic inflammatory pathways.
I Balan, R Patterson, G Boero, H Krohn, TK O’Buckley, S Meltzer-Brody, AL Morrow
EBioMedicine, 2023•thelancet.com.